It is reported that the incidence of pathologic fractures of the vertebra in patients with malignancy is approximately % 10 (9). Although the most of the patients with spinal metastases are asymptomatic, approximately one- third of patients could become symptomatic and present themselves with refractory pain and neurological impairment (10,11) Persistent back pain and neurologic dysfunction due to neural compression and spinal instability are characteristic symptoms in symptomatic spinal metastases (12). When does the surgical intervention necessary is still a matter of debate. Moreover, do the surgical procedures extend the lifespan of the patients with spinal metastases is unknown. We aimed to evaluate the effectiveness of the specific procedure, called corpectomy, to cancer patients with pathologic fracture of the spine and contribution to survive.
The total serum protein concentration (C) was calculated as follows: C (mg/dl) = A sample × concentration of the standard A standard. 22.214.171.124 Albumin Serum albumin was determined using Bromocresol Green (BCG) method (Peter et al 1982). Measurement of serum albumin is based on its quantitative binding to the indicator 5, 5-dicromo-o-cresolsulphonaphthaline (bromocresol green, BCG). Non-haemoloysed serum was mixed with a buffered BCG reagent and incubated at 20-25oC for 5minutes. The absorbance of the sample and that of the standard were measured against the reagent blank at a wavelength of 630nm and albumin was calculated as follows: g/l = Δ A sample / Δ A standard × standard concentration (6%) (Where A = absorbance).
Pitavastatin is slightly unstable in light and hygroscopic. Each film-coated Pitavastatin tablet contains 1.045 mg or 2.09 mg, or 4.18 mg of pitavastatin calcium, which is equivalent to 1 mg or2 mg or 4 mg, respectively of free base and the following inactive ingredients: lactose monohydrate, hypromellose, magnesium stearate,magnesium alumina meta silicate, low substituted hydroxylpropyl cellulose and film coating containing the following inactive ingredients: titanium dioxide, hypromellose, colloidal anhydrous silica and triethyl citrate. 2.2 Mechanism of Action and Pharmacology: Pitavastatin drug competitively inhibits HMG-CoA reductase enzyme, which is a rate-determining enzymeinvolved in the biosynthesis of cholesterol, in the manner of competition with a substrate sothat it inhibits cholesterol synthesis process in liver. As a result of it, the expression of LDL-receptorsand followed by the uptake of the LDL from blood to liver is accelerated,and then the plasma TCdecreases. Further, the sustained inhibition of the cholesterol synthesis in liver decreaseslevels of VLDL(very low density lipoproteins).
(p=0.79).Serum bilurubin shows statistical significant difference both at baseline (p=0.036) & 1 month (p=0.000113) After Intragroup evaluation of all periodontal parameters & serum parameters of CG at baseline and at 1 month shows that there is no statistical significant difference [Table No. 3] but TG shows statistical significant difference between at baseline & 1months in periodontal & serum parameters. [Table no.
INTRODUCTION: Bronchogenic carcinoma is the most common malignancy in the world, accounting for 7% of all deaths in men and women. It is the leading cause of death in industrialized countries and also rising at alarming rates in developing countries. In Pakistan cancer of the lung has been ranked the most frequent malignancy in men in Karachi in the entire 1995- 2002 period. In the 1998-2002 period the incidence rate increased to 25.5 per 100,000 (males) and 4.2 per 100,000 (females). Extensive epidemiologic data clearly establish cigarette smoking as the major cause of lung cancer.
As a prokinetic agent, DOM increases esophageal and gastric peristalsis and improves antroduodenal coordination which facilitates gastric emptying (7, 8). It is administered orally in the dose range of 10-40 mg daily and has elimination half life of 5-7 hrs (9). The short half life of DOM necessitates its frequent
The types of cancers that can cause secondary thrombocytosis are lung, gastrointestinal, and ovarian. What is the most at risk age group? If it is not caused by cancer occurs mostly in women ages fifty to seventy. It is unknown why more women than men develop it. It may develop as early as the age of thirty is also unknown.
Biologic insults including masses, splenomegaly and torsion happen much more frequently then traumatic insults. When torsion occurs the stomach twists causing the spleen to twist on itself since it’s attached to the stomach, when twisted it compromises the blood supply. Torsion is more commonly associated with gastric dilatation-volvulus, occurring more often in large deep chested dogs, it is not recommended to untwist the spleen because it could release any toxins built up into the circulatory system. There are two types of masses, benign and malignant, with neither one showing obvious signs. In several cases the mass isn’t detected for months or until the mass ruptures causing hemorrhage into the abdominal cavity and the patient becomes critical at a rapid speed and infection can be caused by the substances that are normally filtered out by the spleen.
S. Gibbs, S. Schrag, & A. Schuchat, 2004). Studies on the use of intravenous intrapartum antibiotic prophylaxis to prevent early-onset GBS disease in the infant have been ongoing since the 1980s. Clinical trials and well-designed observational studies have shown that intrapartum antibiotic prophylaxis reduces vertical transmission of GBS, as measured by infant colonization or by reduction in early onset disease (Verani et al, 2010). Although early trials suggested an efficacy of 100% for intrapartum antibiotic prophylaxis to prevent early-onset disease among infants born to women with GBS colonization, more recent studies found the effectiveness to be 86%–89% (Lin FY, Brenner RA, Johnson YR, Azimi P.H., Phillips J.B. 3rd, Regan J.A., Clark P., Weisman L.E., Rhoads G.G., Kong F. & Clemens J.D., 2001; Schrag SJ, Zell ER, Lynfield R, Roome A, Arnold KE, Craig AS, Harrison LH, Reingold A, Stefonek K, Smith G, Gamble M, Schuchat A; Active Bacterial Core Surveillance